We are live on ! Find out more
HS

HighVista Strategies Portfolio holdings

AUM $439M
1-Year Est. Return 289.78%
This Fund
S&P 500
This Quarter Est. Return
+35.32%
1 Year Est. Return
+289.78%
3 Year Est. Return
+622.25%
5 Year Est. Return
+856.34%
10 Year Est. Return
+2,866.87%
AUM
$439M
AUM Growth
+$76.4M
Cap. Flow
-$4.42M
Cap. Flow %
-1.01%
Top 10 Hldgs %
28.21%
Holding
185
New
29
Increased
50
Reduced
66
Closed
38

Top Buys

Rank Stock Value
1
CCCC icon
C4 Therapeutics
CCCC
+$4.61M
2
ALKS icon
Alkermes
ALKS
+$4.14M
3
TNGX icon
Tango Therapeutics
TNGX
+$3.85M
4
RLMD icon
Relmada Therapeutics
RLMD
+$3.12M
5
ELVN icon
Enliven Therapeutics
ELVN
+$2.75M

Top Sells

Rank Stock Value
1
TERN
Terns Pharmaceuticals
TERN
+$6.03M
2
NUVL
Nuvalent
NUVL
+$5.8M
3
SLNO
Soleno Therapeutics
SLNO
+$5.53M
4
SYRE icon
Spyre Therapeutics
SYRE
+$5M
5
APGE icon
Apogee Therapeutics
APGE
+$3.01M

Sector Composition

Rank Sector Weight
1 Healthcare 70.95%
2 Technology 8.26%
3 Miscellaneous 6.43%
4 Industrials 4.96%
5 Financials 2.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AVGO icon
76
Broadcom
AVGO
$1.7T
$1.59M 0.36%
4,199
-1,400
-25% -$561K
CLMT icon
77
Calumet Specialty Products
CLMT
$4.7B
$1.58M 0.36%
+44,000
New +$1.48M
Q
78
Qnity Electronics Inc
Q
$24.8B
$1.58M 0.36%
+9,700
New +$1.43M
KOD icon
79
Kodiak Sciences
KOD
$2.29B
$1.58M 0.36%
40,590
-2,979
-7% -$116K
CRDO icon
80
Credo Technology Group
CRDO
$30.9B
$1.58M 0.36%
+5,800
New +$1.15M
KNX icon
81
Knight Transportation
KNX
$11.3B
$1.57M 0.36%
20,100
-2,800
-12% -$194K
BCO icon
82
Brink's
BCO
$4.38B
$1.55M 0.35%
+16,414
New +$1.71M
ALAB icon
83
Astera Labs
ALAB
$49.1B
$1.54M 0.35%
+3,198
New +$849K
SPGI icon
84
S&P Global
SPGI
$133B
$1.54M 0.35%
+3,782
New +$1.6M
MDGL icon
85
Madrigal Pharmaceuticals
MDGL
$12.5B
$1.53M 0.35%
2,852
+254
+10% +$130K
EFX icon
86
Equifax
EFX
$22.2B
$1.52M 0.35%
+9,572
New +$1.63M
RYTM icon
87
Rhythm Pharmaceuticals
RYTM
$7.22B
$1.52M 0.35%
13,657
-3,139
-19% -$284K
SVRA icon
88
Savara
SVRA
$1.1B
$1.49M 0.34%
242,379
-8,620
-3% -$46.3K
DPZ icon
89
Domino's
DPZ
$11.5B
$1.48M 0.34%
+4,991
New +$1.64M
BLTE
90
Belite Bio
BLTE
$6.89B
$1.47M 0.34%
9,554
+1,521
+19% +$233K
MU icon
91
Micron Technology
MU
$1.08T
$1.45M 0.33%
1,260
-2,540
-67% -$1.9M
CIEN icon
92
Ciena
CIEN
$45B
$1.43M 0.33%
2,925
-2,360
-45% -$1.2M
CELC icon
93
Celcuity
CELC
$4.72B
$1.41M 0.32%
13,472
+367
+3% +$42.3K
QXO
94
QXO Inc
QXO
$14B
$1.41M 0.32%
81,420
+55,100
+209% +$1.03M
IMCR icon
95
Immunocore
IMCR
$1.93B
$1.37M 0.31%
43,185
-15,512
-26% -$459K
CGON icon
96
CG Oncology
CGON
$6.59B
$1.34M 0.31%
18,867
-1,047
-5% -$68.4K
USFD icon
97
US Foods
USFD
$22.6B
$1.33M 0.3%
+13,000
New +$1.16M
TDG icon
98
TransDigm Group
TDG
$64B
$1.31M 0.3%
985
-160
-14% -$196K
LITE icon
99
Lumentum
LITE
$76B
$1.3M 0.3%
1,517
-1,600
-51% -$1.43M
FE icon
100
FirstEnergy
FE
$27.2B
$1.24M 0.28%
+26,100
New +$1.24M
2 3
4
5 6

Similar funds

OGM
OnyxPoint Global Management New York $439M AUM 52.19% 1-Year Est. Return
NCM
New Capital Management Houston, Texas $439M AUM 16.55% 1-Year Est. Return
BCC
Bridge City Capital Lake Oswego, Oregon $438M AUM 64.84% 1-Year Est. Return
ASW
Astoria Strategic Wealth Conroe, Texas $438M AUM 16.79% 1-Year Est. Return
CNC
Citizens & Northern Corp Wellsboro, Pennsylvania $438M AUM 26.63% 1-Year Est. Return
TAA
Turiya Advisors Asia Hong Kong $440M AUM 152.81% 1-Year Est. Return
PMA
Prudent Man Advisors Naperville, Illinois $438M AUM 34.49% 1-Year Est. Return
FW
Fairway Wealth Independence, Ohio $437M AUM 19.74% 1-Year Est. Return

HighVista Strategies's Q2 2026 Portfolio in Review

As of Q2 2026, HighVista Strategies held 185 positions worth $439M, up 21% from $362M the previous quarter. Its ten largest holdings account for 28% of the portfolio.

HighVista Strategies's Q2 2026 filing shows 29 new, 50 increased, 66 reduced and 38 closed positions. Its largest new stake was C4 Therapeutics: 1,348,136 shares worth $6.3M. The largest sale was Terns Pharmaceuticals, an estimated $6.03M.

By sector, the portfolio is most concentrated in Healthcare at 71% of assets, up from 67% a quarter earlier, followed by Technology and Miscellaneous.

  • HighVista Strategies's largest Q2 2026 buy was C4 Therapeutics: 1,348,136 shares worth $6.3M.
  • HighVista Strategies added most to Alkermes in Q2 2026, an estimated $4.14M increase.
  • HighVista Strategies's biggest Q2 2026 reduction was Spyre Therapeutics, cutting an estimated $5M.
  • HighVista Strategies fully exited Terns Pharmaceuticals in Q2 2026, selling an estimated $6.03M.
  • HighVista Strategies's ten largest holdings make up 28% of its $439M portfolio in Q2 2026.
  • HighVista Strategies opened 29 new positions and closed 38 in Q2 2026.
  • HighVista Strategies's portfolio value rose 21% quarter-over-quarter to $439M.

Based on HighVista Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.